---
date: "2024-01-13 06:54:45" # 2021-07-14
title: "Zoetis (NYSE:ZTS) Stock Rating Lowered to Buy by StockNews.com"
# image: "images/plots/{{titleSlag}}.png"
author: "justin-guese"
draft: false
---
tickers: <a href='https://finance.yahoo.com/quote/ZTS' target='_blank'>ZTS</a>, <a href='https://finance.yahoo.com/quote/JBARF' target='_blank'>JBARF</a>, <a href='https://finance.yahoo.com/quote/MS' target='_blank'>MS</a> 

source: <a href='https://www.defenseworld.net/2024/01/13/zoetis-nysezts-stock-rating-lowered-by-stocknews-com.html' target='_blank'>Stocknews.com</a>

#### tickers affected by this

| ticker | polarity | why? |
|------------|------------|------------|
| ZTS | positively | ZTS will be affected positively as several investment analysts have given it a "buy" rating and increased their price target, indicating confidence in the stock's potential for growth. Additionally, the company's recent earnings report showed positive results, beating EPS estimates and maintaining a strong net margin. |
| JBARF | positively | In this context, it is not mentioned whether the article is about the ticker JBARF or not. Therefore, I cannot provide a specific reason as to why JBARF would be affected positively by this information. |
| MS | positively | In this context, it is not clear how the ticker MS (Morgan Stanley) would be positively affected by the article about Zoetis (ZTS). There is no direct mention or connection between the two companies in the article. |



#### our strategies and bots using these tickers

None so far...

## summary

# Zoetis (NYSE:ZTS) Stock Rating Lowered by StockNews.com

Zoetis (NYSE:ZTS) has been downgraded by investment analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research report issued on Thursday. This follows recent research reports by other equities research analysts. Jefferies Financial Group reiterated a "buy" rating and set a $230.00 price target on Zoetis shares. Meanwhile, Argus increased their price target on Zoetis from $190.00 to $201.00 and Stifel Nicolaus dropped their price target to $195.00. BNP Paribas initiated coverage on Zoetis with an "outperform" rating and a $237.00 price target. Piper Sandler also increased their price target on Zoetis from $210.00 to $215.00. Overall, nine investment analysts have given a buy rating to Zoetis. MarketBeat.com reports that the consensus rating for the stock is "Buy" with a consensus price target of $222.33.

Zoetis shares opened at $198.94 on Thursday. The company has a quick ratio of 2.16, a current ratio of 3.87, and a debt-to-equity ratio of 1.29. Zoetis has seen a 52-week low of $151.03 and a 52-week high of $201.92. The company has a 50-day simple moving average of $185.96 and a 200-day simple moving average of $180.38. With a market cap of $91.34 billion, Zoetis has a PE ratio of 40.43, a P/E/G ratio of 2.90, and a beta of 0.85.

For its most recent earnings release on November 2nd, Zoetis reported earnings per share (EPS) of $1.36 for the quarter, beating analysts' consensus estimates of $1.35 by $0.01. The company had revenue of $2.15 billion during the quarter, slightly below analyst estimates of $2.17 billion. Zoetis boasts a net margin of 27.24% and a return on equity of 52.22%. Sell-side analysts anticipate that Zoetis will post 5.41 EPS for the current year.

In terms of insider trading, CEO Kristin C. Peck sold 13,000 shares of Zoetis stock, generating $2,298,920.00 in value. Following the completion of the transaction, the chief executive officer retains ownership of 56,843 shares in the company. In addition, EVP Roxanne Lagano sold 923 shares of the stock, valued at $163,795.58. The executive vice president now holds 22,665 shares in the company.

Several hedge funds and institutional investors have recently added to or reduced their stakes in Zoetis. For example, Bank Julius Baer & Co. Ltd Zurich increased its stake by 163,671.8% during the 2nd quarter, now owning 480,424,669 shares valued at $82,733,932,000. Norges Bank acquired a new position in Zoetis during the 4th quarter worth approximately $745,861,000. Meanwhile, Morgan Stanley boosted its stake in Zoetis by 34.6% during the 4th quarter, owning 10,872,704 shares valued at $1,593,395,000. Moneta Group Investment Advisors LLC increased its stake by 124,281.9% during the 4th quarter, now owning 2,332,160 shares valued at $341,778,000. Finally, Arrowstreet Capital Limited Partnership increased its stake by 171.7% during the 1st quarter, holding 3,326,448 shares valued at $627,335,000. Institutional investors and hedge funds now own 89.47% of the companyâ€™s stock.

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products. The company primarily operates in the United States and internationally, commercializing products for livestock (cattle, swine, poultry, fish, and sheep) as well as companion animals (dogs, cats, and horses).

Please see [link to the source article] for more information.

*Note: This article is not endorsed by or affiliated with ai-investing-bots.com. It is written for demonstration purposes only.*